Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norethindrone + mestranol is a combination oral contraceptive containing two types of female hormones: a progestin (norethindrone) and an estrogen (mestranol). This combination works primarily by inhibiting ovulation through suppression of the hypothalamic-pituitary-ovarian axis. Norethindrone acts as a synthetic progestational hormone, while mestranol is a synthetic estrogen that must be demethylated to become biologically active. Together, they alter the cervical mucus and endometrial lining to further prevent fertilization and implantation. The primary indication for this drug is contraception; it may also be used in certain cases for menstrual regulation or treatment of hormonal imbalances[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethindrone + mestranol.